This meeting brings together global decision-makers from both inside and outside of the cell and gene therapy industry.
17/01/2017 - 8:30 am
20/01/2017 - 5:00 pm
The agenda will focus in on R&D, bioprocessing, supply chain & logistics, regulation and cellular immunotherapy and more and the event is expected to attract 850+ attendees and 200+ speakers.
The Cell and Gene Therapy Catapult team will be in attendence and will be taking part in the following sessions:
Day 1 - How are public sector-led initiatives and consortia around the world driving the development and uptake of automated solutions to cell and gene therapy manufacturing? Dr Michael Delahaye, Senior Process Development Scientist, Cell and Gene Therapy Catapult
Day 1 - Regional panel discussion – Europe: caught between a Trump and a BREXIT, Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult
Day 2 - Regional Update, Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult
Day 3 - How uncertainty around the value claims of immunotherapies can be addressed in payer negotiations? Dr Panos Kefalas, Head of Health Economics and Market Access
Day 3 - Market access and reimbursement for immuno-oncology drugs in today healthcare system, Dr Panos Kefalas, Head of Health Economics and Market Access, Cell and Gene Theapy Catapult